Mail

MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

83.75

+0.45 (+0.54%)

As of 9:44AM EDT. Market open.

Stock chart is not supported by your current browser

Previous close	83.30
Open	82.70
Bid	83.30 x 2200
Ask	83.83 x 2200
Day's range	83.37 - 83.82
52-week range	59.80 - 84.27
Volume	559,388
Avg. volume	10,244,975

Market cap	215.626B
Beta (3Y monthly)	0.29
PE ratio (TTM)	26.44
EPS (TTM)	3.17
Earnings date	30 Jul 2019
Forward dividend & yield	2.20 (2.78%)
Ex-dividend date	2019-06-14
1y target est	88.93

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks46 minutes ago
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Business Wire3 hours ago
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Marks First Approval for KEYTRUDA in SCLC
Business Wire3 hours ago
LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Tri
Zacks16 hours ago
Bayer to Invest 5 Billion Euros in Weedkiller Research
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
Zacks16 hours ago
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Market Realist17 hours ago
Merck’s Inorganic Growth Strategy in 2019
On April 2, Merck & Co. issued a press release announcing the successful completion of its cash tender offer for Immune Design, with 86.75% of the target’s total outstanding common stock tendered on a fully diluted basis.
Zacks18 hours ago
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Market Realist19 hours ago
How Are Merck’s Revenues Trending in 2019?
On its first-quarter earnings conference call, Merck & Co. (MRK) guided for 2019 revenue of $43.9 billion–$45.1 billion, a YoY (year-over-year) rise of 4%–7% driven by its Oncology, Hospital and Specialty, Vaccines, and Animal Health segments.
Market Realist20 hours ago
What Analysts Recommend for Merck and AstraZeneca in June
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
Zacks4 days ago
Agilent Announces Receipt of FDA Approval for pharmDX Assay
Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
Zacks4 days ago
3 Big Pharma Stocks to Buy Right Now
These big pharma stocks all have a Zacks Rank 2 or better.
Barrons.com4 days ago
Merck Plans Its First Investor Day in 5 Years. Here’s What to Watch.
Analysts say that the event will be vital for the pharmaceutical company as it seeks to show investors it can build on a strong run in recent years.
Zacks4 days ago
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
The index traversed a volatile week, guided largely by trade-related developments.
Zacks4 days ago
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Zacks5 days ago
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Zacks5 days ago
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
Here are five reasons why investors may consider betting on Merck (MRK) stock
Reuters5 days ago
IBM, Walmart, Merck in blockchain collaboration with FDA
The companies said they would work with consultancy KPMG to create a shared blockchain network that will allow real-time monitoring of products in the pharmaceutical supply chain. The project has been authorized under the U.S. Drug Supply Chain Security Act (DSCSA) that was set up to increase regulatory oversight of counterfeit, stolen, contaminated or otherwise harmful drugs. The FDA has previously used the DSCSA to issue a warning letter to drug distributor McKesson Corp for violations involving opioid medications.
Zacks6 days ago
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Zacks6 days ago
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Financial Times6 days ago
Ebola outbreak in Congo causes first death in Uganda
A five-year-old boy has died from Ebola in Uganda and two more people have been infected in the first known cases of the virus crossing a border since the outbreak began in eastern Congo last year. Health experts on Wednesday were racing to discover how the boy’s relatives entered Uganda on June 9 and with whom they might have come into contact. Jeremy Farrar, director of Wellcome, a UK health charity, said that the epidemic, the second worst in history, had reached “a truly frightening phase”.
Zacks6 days ago
Boost Your Portfolio's Health With These 3 Big Drug Stocks
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Zacks7 days ago
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Zacks7 days ago
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Business Wire7 days ago
FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose T
Zacks8 days ago
Merck (MRK) Gains But Lags Market: What You Should Know
In the latest trading session, Merck (MRK) closed at $82.48, marking a +0.02% move from the previous day.